Management of atrial fibrillation in patients with chronic obstructive pulmonary disease

Journal of Cardiovascular Nursing

Volumn 20, Issue 2, 2005, Pages 133-140

  Lopez, Carmen M ^a   House Fancher, Mary Ann ^a  

^a The Heart and Vascular Cardiology Group   (United States)

Author keywords

Atrial fibrillation; Cardiac arrhythmia; Chronic obstructive pulmonary disease (COPD); Treatment guidelines

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN;

CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR ACCIDENT; DIGOXIN; HUMANS; PRACTICE GUIDELINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 20644434703     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200503000-00009     Document Type: Article

References (20)

1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. J Am Coll Cordiol. 2001;38:1266i-1xx.
2. Rich S, McLaughlin VV. Pulmonary hypertension. In: Braunwald, Zipes, Libby, Bonow, eds. Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Philadelphia: Elsevier Saunders; 2005:chapter 67.
3. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest. 2000;117:10S.
4. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;197:1514.
5. Buch P, Friberg J, Scharling H., Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003;21(6): 1012-1016.
6. Hanania NA. Pharmacologic management of COPD: an update from Chest 2004. Available at:. Accessed December 12, 2004.
7. Pedersen OD et al. Prevalence, prognostic significance and treatment of atrial fibrillation and CHF with particular reference to the DIAMOND study. CHF. 2004;9(6): 333-340.
8. Olsen CM. New atrial fib guidelines target patients with pulmonary disease. Pulm Rev. 2001;6(10): Available at:. Accessed January 31, 2005.
9. Linda J, Maureen M. Atrial fibrillation: beyond. Learn to recognize and manage atrial fibrillation in its various forms. Crit Care Choices. 2003;33:4-10.
10. Aizer A, Fuster V. Atrial fibrillation. Web MD Scientific American Medicine 2004. Available at:. Retrieved from January 9, 2004.
11. Kohute ML. New concepts in the management of atrial fibrillation. Clin Trends Pharm Pract. 2001;5(3):39-51.
12. Camm JA. Safety of antiarrhythmic agents: the final frontier in treating atrial fibrillation? Available at:. Accessed September 10, 2004.
13. Dresing T, Schweikert R. Atrial fibrillation. Cleveland Clinic 2002. Available at:. Accessed September 8, 2004.
14. Dell'orfano J et al. Drugs for conversion of atrial fibrillation. August 1998. American Family Physician. AAFP annual clinical focus on prevention and management of cardiovascular disease. Available at:. Accessed September 8, 2004.
15. Wyse DG et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.
16. McCabe P, Geoffroy S. Atrial fibrillation: the newest frontier in arrhythmia management. Prog Cardiovasc Nurs. 2002;17(3):110-123, 141.
17. Chopra IJ, Baber K. Use of oral cholecystographic agents in the treatment of amiodarone-induced hyperthyroidism. J Clin Endocrinol Metab. 2001;86:4707-4710.
18. Rotmensch HH et al. Possible association of pneumonitis with amiodarone therapy. Am Heart J. 1980;100(3):412-413.
19. Hilleman D, Miller MA, Parker R, et al. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy. 1998;18(6, pt 2):138S-145S.
20. Martin WJ II, Rosenow EC III. Amiodarone pulmonary toxicity: recognition and pathogenesis, Part I. Chest. 1988;93:1067-1075.